Tobira Development (TBRA) Getting Somewhat Favorable News Coverage, Study Finds

News headlines about Tobira Development (NASDAQ:TBRA) have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tobira Development earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.7151388228664 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Tobira Development (TBRA) traded up $0.27 during midday trading on Thursday, reaching $42.09. 521,800 shares of the company traded hands, compared to its average volume of 251,055. Tobira Development has a fifty-two week low of $3.76 and a fifty-two week high of $42.33. The company has a debt-to-equity ratio of 0.44, a quick ratio of 5.38 and a current ratio of 5.38.

TRADEMARK VIOLATION NOTICE: This piece was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2017/11/23/tobira-development-tbra-getting-somewhat-favorable-news-coverage-study-finds.html.

Tobira Development Company Profile

Tobira Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company’s product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure.

Insider Buying and Selling by Quarter for Tobira Development (NASDAQ:TBRA)

What are top analysts saying about Tobira Development Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tobira Development Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit